Skip to content

MBX Biosciences

US · MBX #2567 by market cap Listed 2024
49.55 -3.86 -7.23%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About MBX Biosciences

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Founded
2018
CEO
Mr. Stephen L. Hoerter
Employees
63
Headquarters
Carmel, Indiana, United States of America
Fiscal year end
12-31
Website
mbxbio.com

Company profile

Exchange
US
Symbol
MBX
Market-cap rank
#2567
Listing date
2024-09-13
Market cap
2.46B
Float cap
1.55B
Shares out
49.66M
Float shares
31.23M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

MBX Biosciences discussion 0 comments

Add a comment